Contact

Prospective Assessment of CMV Immunity in High-Risk Donor Seropositive (D+) Recipient Seronegative (R-) Liver Transplant Recipients Receiving Either Preemptive Therapy or Prophylaxis

Ajit P Limaye et.al. ,The Journal of Infectious Diseases (2019) - PMID: n.a.

Product(s) used in this publication: PepMix™ Peptide Pools

Abstract

n.a.

Stay in touch and be the first to receive the latest news!